GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.

GSK plc American Depositary Shares (Each representing two)

GlaxoSmithKline ( ($GB:GSK) ) has provided an update. GSK disclosed that Maya Martinez-Davis, its President for the US, acquired a small number of ...

GSK Reports Executive Notional ADS Acquisition Under Savings Plan

GlaxoSmithKline ( ($GB:GSK) ) has issued an announcement. GSK reported that all 25 resolutions at its 26th Annual General Meeting, held as a hybrid...

GSK Wins Strong Shareholder Backing at 26th Annual General Meeting

In a report released today, Emmanuel Papadakis from Deutsche Bank reiterated a Hold rating on GlaxoSmithKline, with a price target of p1,900.00. Ac...

Deutsche Bank  Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

The latest update is out from GlaxoSmithKline ( ($GB:GSK) ). GSK has granted a notional Ordinary Share award to Roanne Parry under its Deferred Inv...

GSK grants long-term deferred award to new Chief People Officer

GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has announced that its issued share capital as of 30 April 2026 stands at 4,316,202,660 ord...

GSK Updates Market on Total Voting Rights and Share Capital

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline on April 29 and set a price target of p1,500.00. The company’s share...

Kepler Capital  Remains a Hold on GlaxoSmithKline (GSK)

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline today and set a price target of £18.70. Sharma covers the Healthcare...

Goldman Sachs Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Here’s a quick look at today’s key earnings reports from major publicly traded companies. Investors will be watching closely for updates on financi...

These Are the Stocks Reporting Earnings Today – April 29, 2026

Deutsche Bank  Remains a Hold on GlaxoSmithKline (GSK)

The latest announcement is out from GlaxoSmithKline ( ($GB:GSK) ). GSK has confirmed the vesting of a conditional share award granted in 2023 to Ch...

GSK CFO Julie Brown Receives Vested Performance Share Award

GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK disclosed that Maya Martinez-Davis, the company’s President for the US, acquired notional A...

GSK Reports Routine ADS Acquisition by US President Martinez-Davis

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK disclosed that Chief People Officer Diana Conrad acquired American Depositary Share...

GSK Discloses Dividend-Funded ADS Purchase by Chief People Officer

J.P. Morgan analyst Zain Ebrahim maintained a Sell rating on GlaxoSmithKline today and set a price target of £17.00. According to TipRanks, Ebrahim...

GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan

The latest update is out from GlaxoSmithKline ( ($GB:GSK) ). GSK has continued its ongoing share buyback programme, repurchasing 330,000 ordinary s...

GSK Adds 330,000 Shares to Treasury in Ongoing Buyback

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK Tests Next-Gen Pneumonia Shot in Mid-Life Adults. The Phase 1 trial...

GSK’s New Pneumonia Vaccine Trial Targets a Growing Adult Market

The latest announcement is out from GlaxoSmithKline ( ($GB:GSK) ). GSK has reported a series of routine executive share transactions linked to its ...

GSK Executives See Notional Shareholdings Rise Through Dividend Reinvestment

An update from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK plc disclosed a series of routine share transactions by senior executives under ...

GSK Executives Acquire Shares Under Company Reward Plan

Citi analyst Graham Parry maintained a Hold rating on GlaxoSmithKline today and set a price target of £22.50. According to TipRanks, Parry is a 2-s...

GlaxoSmithKline (GSK) Gets a Hold from Citi

GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has disclosed a series of share acquisitions by senior executives and persons closely assoc...

GSK Executives Reinvest Dividends in Routine Insider Share Purchases

In a report released today, Zain Ebrahim from J.P. Morgan maintained a Sell rating on GlaxoSmithKline, with a price target of £17.00. According to ...

J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)

Jefferies analyst Michael Leuchten maintained a Buy rating on GlaxoSmithKline today and set a price target of £25.00. According to TipRanks, Leucht...

GlaxoSmithKline (GSK) Receives a Buy from Jefferies

Shares in GlaxoSmithKline ($GSK) fell marginally early Monday even after the British drugmaker trumpeted the commercial potential of Morez, its exp...

“A Blockbuster? Yes, Absolutely” — GlaxoSmithKline (GSK) Stock Slides despite Morez Hype

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline today and set a price target of £19.20. According to TipRanks, Sharm...

Market Cap	$104.92B	P/E Ratio	10.37
52W High	$61.70	52W Low	$35.45
Div Yield	159.2%	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	58.9%
Overall Score	24	Value Score	--
Quality Score	21	Technical Score	27

EPS Current Est	$4.91	EPS Next Est	$5.13
EPS Growth Est	+4.5%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GSK	$50.90	+2.19%	4.85M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GSK	$50.90	+2.2%	4.85M
3
4
5
6

GSK

GSK

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get GSK plc American Depositary Shares (Each representing two) Data in Excel

Get GSK plc American Depositary Shares (Each representing two) Data in Excel